EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

CYP2C19 c. 681G >A Is not in Complete Linkage Disequilibrium With c.332‐ 23A >G: Implications for Pharmacogenetic Testing

Amy J Turner iD, Erin C Boone iD, Cyrine E Haidar iD, Wenjian Yang iD, Ashley D Derezinski iD, Andrew Haddad iD, Philip E Empey iD, Ulrich Broeckel iD, Andrea Gaedigk iD

Clinical and Translational Science · 2026-08 · 19 (8)

DOI: 10.1111/cts.70684 ↗

At a glance

Journal article in Clinical and Translational Science, published online on 2026-07-31. Written by Amy J Turner and 8 co-authors. Institution: RPRD Diagnostics LLC, Milwaukee, Wisconsin, USA. Major MEDLINE topics: Cytochrome P-450 CYP2C19, Pharmacogenomic Testing, Linkage Disequilibrium, Pharmacogenomic Variants. 22 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIH HHS, National Institutes of Health.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

CYP2C19 plays an important role in the metabolism of many medications, including the antiplatelet agent clopidogrel, the antifungal agent voriconazole, selective serotonin reuptake inhibitors, select tricyclic antidepressants, and proton pump inhibitors. The Clinical Pharmacogenetics Implementation Consortium has published several guidelines emphasizing the importance of CYP2C19 genotype‐guided therapy to optimize patient outcomes. Formerly, the no function CYP2C19*2 allele was defined by three variants, c.332‐23A>G (splice defect), c.681G>A (splice defect), and c.991A>G (p.I331V). The discovery of two new haplotypes, one containing only a single variant, c.681G>A, and another with only c.681G>A and c.991A>G, challenged the assumption that c.681G>A always occurred together with c.332‐23A>G. PharmVar designated these new haplotypes as CYP2C19*2.018 and *2.019 , respectively, prompting the revision of the CYP2C19*2 core allele to be defined solely by the single variant, c.681G>A. Although the variants interrogated to identify CYP2C19*2 and *35 remain the same, subjects who are heterozygous for c.332‐23A>G (present on most CYP2C19*2 and all *35 alleles) and c.681G>A (present on all CYP2C19*2 alleles) may, in rare cases, have a CYP2C19*2/*35 poor metabolizer diplotype (variants in trans ) and not a CYP2C19*1/*2 intermediate metabolizer diplotype (variants in cis ). CYP2C19*2 alleles with c.681G>A, but not c.332‐23A>G, were found in subjects across diverse populations and are estimated to have a frequency around 0.03%. These findings, along with the revision of the CYP2C19*2 core allele definition, have implications for variant testing, test interpretation and reporting.

Subjects

MeSH terms (MEDLINE)

Cytochrome P-450 CYP2C19Pharmacogenomic TestingLinkage DisequilibriumPharmacogenomic VariantsHumansHaplotypesAllelesClopidogrelVoriconazole

Substances

Cytochrome P-450 CYP2C19CYP2C19 protein, humanClopidogrelVoriconazole

Authors and institutions

  • RPRD Diagnostics LLC, Milwaukee, Wisconsin, USA.
  • Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy, Kansas City, Missouri, USA.
  • Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
  • Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
  • School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.

ORCID profiles: Amy J Turner, Erin C Boone, Cyrine E Haidar, Wenjian Yang, Ashley D Derezinski, Andrew Haddad, Philip E Empey, Ulrich Broeckel, Andrea Gaedigk

Funding

  • NIH HHS
  • National Institutes of Health

Cite

APA

Turner, A. J., Boone, E. C., Haidar, C. E., Yang, W., Derezinski, A. D., Haddad, A., Empey, P. E., Broeckel, U., & Gaedigk, A. (2026). CYP2C19 c. 681G >A Is not in Complete Linkage Disequilibrium With c.332‐ 23A >G: Implications for Pharmacogenetic Testing. Clinical and Translational Science, 19(8). https://doi.org/10.1111/cts.70684

Vancouver

Turner AJ, Boone EC, Haidar CE, Yang W, Derezinski AD, Haddad A, et al. CYP2C19 c. 681G >A Is not in Complete Linkage Disequilibrium With c.332‐ 23A >G: Implications for Pharmacogenetic Testing. Clinical and Translational Science. 2026;19(8). doi:10.1111/cts.70684

BibTeX
@article{Turner2026,
  author = {Turner, Amy J and Boone, Erin C and Haidar, Cyrine E and Yang, Wenjian and Derezinski, Ashley D and Haddad, Andrew and Empey, Philip E and Broeckel, Ulrich and Gaedigk, Andrea},
  title = {CYP2C19 c. 681G >A Is not in Complete Linkage Disequilibrium With c.332‐ 23A >G: Implications for Pharmacogenetic Testing},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {8},
  doi = {10.1111/cts.70684}
}
Start for free →